Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 25,000 shares at $49.07 ($1.2M) on 2025-08-05, disclosed to the SEC on 2025-08-07.
Scheduled sale ($1.2M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $49.07 | 5,538 | $272K | 22.0% |
| 2 | $49.07 | 5,538 | $272K | 22.0% |
| 3 | $49.49 | 6,962 | $345K | 28.0% |
| 4 | $49.49 | 6,962 | $345K | 28.0% |
| Total | $49.30 avg | 25,000 | $1.2M | 100% |
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-06-20 | $124K | — | Filing → |